Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDUWBF)

Drug Name
JNJ-17203212 Drug Info
Synonyms
JNJ-17203212; 821768-06-3; JNJ 17203212; UNII-71JE0C439X; CHEMBL254778; 71JE0C439X; 4-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide; 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide; JFRYYGVYCWYIDQ-UHFFFAOYSA-N; 4-(3-(trifluoromethyl)pyridin-2-yl)-N-(5-(trifluoromethyl)pyridin-2-yl)piperazine-1-carboxamide; JNJ17203212; SCHEMBL138342; GTPL4228; CTK5E9468; C17H15F6N5O; DTXSID50462856; AOB2189; SYN5009; MolPort-006-822-716
Indication
Disease Entry ICD 11 Status REF
Cough MD12 Investigative [1]
Cross-matching ID
PubChem CID
11339118
CAS Number
CAS 821768-06-3
TTD Drug ID
DMDUWBF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Transient receptor potential cation channel V1 (TRPV1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Capsaicin DMGMF6V Back pain ME84.Z Approved [3]
CNTX-4975 DMB4JPG Knee osteoarthritis FA01 Phase 3 [4]
XEN-D0501 DMG7PDY Overactive bladder GC50.0 Phase 2 [5]
Resiniferatoxin DMP62L5 Neuropathic pain 8E43.0 Phase 2 [6]
PAC-14028 DM3816P Atopic dermatitis EA80 Phase 2 [7]
GRC-15300 DMWXJSZ Pain MG30-MG3Z Phase 2 [8]
DWP-05195 DMQKU2F Neuropathic pain 8E43.0 Phase 2 [9]
SB-705498 DMRYHWI Rhinitis FA20 Phase 2 [10]
GRC-6211 DMZ0D3V Asthma CA23 Phase 1 [11]
ABT-102 DMJFWPR Chronic pain MG30 Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Transient receptor potential cation channel V1 (TRPV1) TTMI6F5 TRPV1_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4228).
2 The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J Med Chem. 2007 May 31;50(11):2589-96.
3 Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol. 2007;(179):155-71.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol. 2011 Dec;72(6):921-31.
6 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
7 Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012 Mar;35(3):393-6.
8 The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest. 2010 November 1; 120(11): 3753-3759.
9 TRPV1 Antagonists as Analgesic Agents. The Open Pain Journal, 2013, 6, (Suppl 1: M11), 108-118 .
10 Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
11 GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol. 2009 Jan;181(1):379-86.